GlycoVaxyn is a vaccine developer focused on creating new antibacterial conjugate vaccines using its biological conjugation platform technology
GlycoVaxyn is a vaccine developer focused on creating new antibacterial conjugate vaccines using its biological conjugation platform technology. The company is in Phase I clinical trials for a vaccine candidate against E. coli infections and is expected to launch a Phase I study for a vaccine against Shigellosis.